奈伐库单抗
化合物
奈伐库单抗（INN：Nesvacumab），或译奈伐苏单抗、耐斯伐库单抗，是一种实验性单克隆抗体，最初设计用于治疗癌症。它的靶标是血管生成素2。[1][2]截至2017年5月，该药物正处于治疗糖尿病性黄斑水肿的II期临床试验中。[3][4]该药物由再生元制药公司开发。
| 单克隆抗体 | |
|---|---|
| 种类 | 完整抗体 |
| 目标 | 血管生成素2 |
| 临床资料 | |
| ATC码 |
|
| 法律规范状态 | |
| 法律规范 |
|
| 识别信息 | |
| CAS号 | 1296818-77-3 |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| 化学信息 | |
| 化学式 | C6440H9966N1722O2008S38 |
| 摩尔质量 | 144,860.89 g·mol−1 |
参考资料
编辑- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Nesvacumab （页面存档备份，存于互联网档案馆）, American Medical Association.
- ^ Hussain RM, Neiweem AE, Kansara V, Harris A, Ciulla TA. Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease. Expert Opinion on Investigational Drugs. October 2019, 28 (10): 861–869. PMID 31513439. doi:10.1080/13543784.2019.1667333.
- ^ Clinical trial number NCT02713204 for "Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX)" at ClinicalTrials.gov
- ^ Clinical trial number NCT02712008 for "Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema (RUBY)" at ClinicalTrials.gov